Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614825 | 0.91 | NPC1 (0.31) | NPC1RAB9APTGDR2CA2 | |
| SCHEMBL707949 | 0.88 | KDM1A (0.32) | PTPN1USP28 | |
| SCHEMBL29387214 | 0.88 | KDM1A (0.32) | PTPN1USP28 | |
| SCHEMBL25619918 | 0.87 | NPC1 (0.31) | USP28NPC1RAB9APTGDR2CA2 | |
| SCHEMBL2034552 | 0.86 | PTPN1 (0.33) | PTPN1USP28NPC1RAB9APTGDR2 | |
| SCHEMBL856379 | 0.86 | KDM1A (0.39) | USP28NPC1RAB9APTGDR2 | |
| SCHEMBL523311 | 0.84 | GRIA1 (0.35) | USP28CA2 | |
| SCHEMBL597251 | 0.84 | PTPN1 (0.36) | PTPN1PTGDR2CA2 | |
| SCHEMBL24697715 | 0.83 | KDM1A (0.36) | PTPN1 | |
| SCHEMBL24133366 | 0.82 | ALOX15 (0.39) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122491-A1 | FUSED BICYCLIC ARYL COMPOUNDS FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS, LLC (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-10000454-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-03-23 | — | — | US | disclosed |
| US-20170000132-A1 | BENZOXABOROLE FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-01-05 | — | — | US | disclosed |
| US-20170000132-A1 | BENZOXABOROLE FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-01-05 | — | — | US | disclosed |
| US-20170000132-A1 | BENZOXABOROLE FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-01-05 | — | — | US | disclosed |
| EP-3086644-A1 | BENZOXABOROLE FUNGICIDES | Syngenta Participations AG (CH) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015176267-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2015097237-A1 | BENZOXABOROLE FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2015-07-02 | — | — | WO | disclosed |
| US-20110275703-A1 | SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275703-A1 | SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100093744-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100093744-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-04-15 | — | — | US | disclosed |
| CN-101495494-A | Fused ring spiroketal derivative and use thereof as therapeutic agent for diabetes | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-07-29 | — | — | CN | disclosed |
| EP-2072522-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-06-24 | — | — | EP | disclosed |
| EP-2048152-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS DRUG FOR TREATING DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000454-B2 | Antidiabetic tricyclic compounds | GPR119, GPR65, GPR52 | PTPN1 1690/4885USP28 3762/4885NPC1 283/4885 |
| US-20100093744-A1 | THIOGLUCOSE SPIROKETAL DERIVATIVE AND USE THEREOF AS THERAPEUTIC AGENT FOR DIABETES | SLC5A1, SLC5A2, GCKR | PTPN1 327/4885USP28 4852/4885NPC1 1218/4885 |
| US-20100234609-A1 | FUSED RING SPIROKETAL DERIVATIVE AND USE THEREOF AS ANTI-DIABETIC DRUG | REN, WNK1, GCKR | PTPN1 1379/4885USP28 4575/4885NPC1 2342/4885 |
| US-20170000132-A1 | BENZOXABOROLE FUNGICIDES | CYP4X1, BROX, CYP1B1 | PTPN1 839/4885USP28 2662/4885NPC1 1614/4885 |
| US-20110275703-A1 | SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES | SLC5A1, OR10J3, AKR1C3 | PTPN1 2521/4885USP28 4812/4885NPC1 711/4885 |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | PTPN1 1690/4885USP28 3762/4885NPC1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.